About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a company based in Pasadena (United States) founded in 1989 was acquired by Regal Rexnord in November 2021. It operates as a HealthTech. Arrowhead Pharmaceuticals has raised $110.98 million across 13 funding rounds from investors including Silence Therapeutics, Orbimed and Regal Rexnord. The company has 609 employees as of September 30, 2024. Arrowhead Pharmaceuticals offers products and services including Plozasiran (ARO-APOC3), Zodasiran (ARO-ANG3), and ARO-RAGE. Arrowhead Pharmaceuticals operates in a competitive market with competitors including Merck, AbbVie, Lilly, Biogen and Roche, among others.
- Headquarter Pasadena, United States
- Employees 609 as on 30 Sep, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Arrowhead Pharmaceuticals, Inc.
-
Annual Revenue
$3.55 M-98.52as on Sep 30, 2024
-
Net Profit
$-599.49 M-192.04as on Sep 30, 2024
-
EBITDA
$-582.49 M-202.58as on Sep 30, 2024
-
Total Equity Funding
$110.98 M (USD)
in 13 rounds
-
Latest Funding Round
$7.2 M (USD), Post-IPO
Dec 11, 2017
-
Investors
Silence Therapeutics
& 6 more
-
Employee Count
609
as on Sep 30, 2024
-
Acquired by
Regal Rexnord
(Nov 24, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ARWR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals offers a comprehensive portfolio of products and services, including Plozasiran (ARO-APOC3), Zodasiran (ARO-ANG3), and ARO-RAGE. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Developed to reduce triglycerides in severe hypertriglyceridemia patients.
Designed to lower LDL in dyslipidemia treatment cases.
Created for treating inflammatory pulmonary diseases effectively.
Unlock access to complete
Leadership Team
35 people
Senior Team
19 people
Software Development Team
18 people
Operations Team
11 people
Data Analysis and Operations Team
9 people
Scientist Team
7 people
Finance and Accounting
6 people
Human Resources and Administration
4 people
Unlock access to complete
Funding Insights of Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals has successfully raised a total of $110.98M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $7.2 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Post-IPO — $7.2M
-
First Round
First Round
(11 Aug 2009)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2017 | Amount | Post-IPO - Arrowhead Pharmaceuticals | Valuation |
investors |
|
| Jan, 2017 | Amount | Post-IPO - Arrowhead Pharmaceuticals | Valuation |
investors |
|
| Sep, 2016 | Amount | Post-IPO - Arrowhead Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Silence Therapeutics, Orbimed and Regal Rexnord. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are facilitated by Amgen-backed entity.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Arrowhead Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Arrowhead Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Arrowhead Pharmaceuticals Comparisons
Competitors of Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, AbbVie, Lilly, Biogen and Roche, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| domain | founded_year | HQ Location |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| domain | founded_year | HQ Location |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
|
| domain | founded_year | HQ Location |
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Arrowhead Pharmaceuticals
Frequently Asked Questions about Arrowhead Pharmaceuticals
When was Arrowhead Pharmaceuticals founded?
Arrowhead Pharmaceuticals was founded in 1989 and raised its 1st funding round 20 years after it was founded.
Where is Arrowhead Pharmaceuticals located?
Arrowhead Pharmaceuticals is headquartered in Pasadena, United States. It is registered at Pasadena, California, United States.
Who is the current CEO of Arrowhead Pharmaceuticals?
Christopher Anzalone is the current CEO of Arrowhead Pharmaceuticals.
Is Arrowhead Pharmaceuticals a funded company?
Arrowhead Pharmaceuticals is a funded company, having raised a total of $110.98M across 13 funding rounds to date. The company's 1st funding round was a Post-IPO of $56.5M, raised on Aug 11, 2009.
How many employees does Arrowhead Pharmaceuticals have?
As of Sep 30, 2024, the latest employee count at Arrowhead Pharmaceuticals is 609.
What is the annual revenue of Arrowhead Pharmaceuticals?
Annual revenue of Arrowhead Pharmaceuticals is $3.55M as on Sep 30, 2024.
What does Arrowhead Pharmaceuticals do?
Arrowhead Pharmaceuticals is engaged in the development of innovative therapeutics using RNA interference (RNAi) technology. The company targets genes causing diseases in areas such as cardiometabolic disorders, severe hypertriglyceridemia, dyslipidemia, cardiovascular disease, and pulmonary inflammatory diseases. Solutions are built on the proprietary TRiM platform, which leverages natural pathways to silence disease-causing genes. Clinical trials are conducted across multiple phases to address significant unmet medical needs. The portfolio includes drug candidates like Plozasiran, Zodasiran, and ARO-RAGE, aimed at diverse therapeutic areas. Operations span various global locations to support research and development efforts.
Who are the top competitors of Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals's top competitors include Merck, Roivant Sciences and Amgen.
What products or services does Arrowhead Pharmaceuticals offer?
Arrowhead Pharmaceuticals offers Plozasiran (ARO-APOC3), Zodasiran (ARO-ANG3), and ARO-RAGE.
Is Arrowhead Pharmaceuticals publicly traded?
Yes, Arrowhead Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ARWR.
Who are Arrowhead Pharmaceuticals's investors?
Arrowhead Pharmaceuticals has 7 investors. Key investors include Silence Therapeutics, Orbimed, Regal Rexnord, RTW Investments, and RA Capital.
What is Arrowhead Pharmaceuticals's ticker symbol?
The ticker symbol of Arrowhead Pharmaceuticals is ARWR on NASDAQ.